Isis Pharmaceuticals (ISIS) Reports Earnings: It’s A Beat

Isis Pharmaceuticals, Inc. (ISIS) shares are up $2.21, or 3.28%, to $69.41 in early trading Friday after the company reported its fourth quarter earnings results.

The firm reported non-GAAP earnings of $0.32 per share on revenues of $84.9 million, up 101.2% from a year ago. Analysts were expecting EPS of $0.04 on revenues of $74.58 million. In the last reported quarter, Isis recorded a negative earnings surprise of nearly 10%.

For the full-year 2014, revenue was $214.2 million, compared to $147.3 million for the same periods in 2013. Isis said its strong financial performance in 2014 was a result “of the successful execution of its business strategy, its advancing pipeline and the demonstration that antisense is an efficient and effective drug discovery technology.”

On valuation measures, Isis Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 3.3 million shares, trade at a P/E to growth ratio of (4.93). The median Wall Street price target on the name is $68.00 with a high target of $80.00. Currently ticker boasts 7 ‘Buy’ endorsements, compared to 3 ’Holds’ and 1 ‘Sell’.

Profitability-wise, ISIS has a t-12 profit and operating margin of (54.98%) and (41.41%), respectively. The $8.10 billion market cap company reported $728.8 million in cash – a more than $150 million increase over its cash guidance of $575 million – versus $234.76 million in debt in its most recent quarter.

ISIS currently prints a one year return of 20.15% and a year-to-date return of around 9%.

The chart below shows where the equity has traded over the last 52 weeks.

Isis Pharmaceuticals Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company was founded in 1989 and is headquartered in Carlsbad, California.

Be the first to comment

Leave a Reply

Your email address will not be published.


*